Catálogo de publicaciones - revistas

Compartir en
redes sociales


Nature

Resumen/Descripción – provisto por la editorial en inglés
Nature is a weekly international journal publishing the finest peer-reviewed research in all fields of science and technology on the basis of its originality, importance, interdisciplinary interest, timeliness, accessibility, elegance and surprising conclusions. Nature also provides rapid, authoritative, insightful and arresting news and interpretation of topical and coming trends affecting science, scientists and the wider public.
Palabras clave – provistas por la editorial

No disponibles.

Disponibilidad
Institución detectada Período Navegá Descargá Solicitá
No detectada desde jul. 2012 / hasta dic. 2023 Nature.com
No detectada desde jul. 2006 / hasta ago. 2012 Ovid

Información

Tipo de recurso:

revistas

ISSN impreso

0028-0836

ISSN electrónico

1476-4687

Editor responsable

Springer Nature

País de edición

Reino Unido

Fecha de publicación

Tabla de contenidos

Japanese fund to create ‘Ivy League’ gives first award to just one university

Anna Ikarashi

Palabras clave: Multidisciplinary.

Pp. No disponible

Valley Fever Is a Growing Fungal Threat to Outdoor Workers

Ashli Blow

Palabras clave: Multidisciplinary.

Pp. S38-S39

Global effects of marine protected areas on food security are unknown

Daniel OvandoORCID; Owen Liu; Renato Molina; Ana ParmaORCID; Cody Szuwalski

Palabras clave: Multidisciplinary.

Pp. E34-E36

For Health Equity, Location Matters

Lauren Gravitz

Palabras clave: Multidisciplinary.

Pp. S24-S24

Multistable sheets with rewritable patterns for switchable shape-morphing

A. S. MeeussenORCID; M. van HeckeORCID

Palabras clave: Multidisciplinary.

Pp. 516-520

Distinguishing features of Long COVID identified through immune profiling

Jon KleinORCID; Jamie Wood; Jillian Jaycox; Rahul M. DhodapkarORCID; Peiwen LuORCID; Jeff R. Gehlhausen; Alexandra Tabachnikova; Kerrie Greene; Laura Tabacof; Amyn A. Malik; Valter Silva MonteiroORCID; Julio SilvaORCID; Kathy Kamath; Minlu ZhangORCID; Abhilash Dhal; Isabel M. Ott; Gabrielee Valle; Mario Peña-Hernandez; Tianyang MaoORCID; Bornali BhattacharjeeORCID; Takehiro TakahashiORCID; Carolina LucasORCID; Eric SongORCID; Dayna Mccarthy; Erica Breyman; Jenna Tosto-Mancuso; Yile DaiORCID; Emily Perotti; Koray Akduman; Tiffany J. Tzeng; Lan Xu; Anna C. Geraghty; Michelle MonjeORCID; Inci YildirimORCID; John Shon; Ruslan MedzhitovORCID; Denyse Lutchmansingh; Jennifer D. Possick; Naftali KaminskiORCID; Saad B. OmerORCID; Harlan M. KrumholzORCID; Leying Guan; Charles S. Dela CruzORCID; David van DijkORCID; Aaron M. RingORCID; David PutrinoORCID; Akiko IwasakiORCID

Palabras clave: Multidisciplinary.

Pp. No disponible

Vaccine specialist Peter Hotez: scientists are ‘under attack for someone else’s political gain’

Julian Nowogrodzki

Palabras clave: Multidisciplinary.

Pp. 681-682

Second malaria vaccine to win global approval is cheaper and easier to make

Miryam Naddaf

Pp. No disponible

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

Christina K. BaumgartnerORCID; Hakimeh Ebrahimi-Nik; Arvin Iracheta-VellveORCID; Keith M. Hamel; Kira E. OlanderORCID; Thomas G. R. Davis; Kathleen A. McGuire; Geoff T. Halvorsen; Omar I. AvilaORCID; Chirag H. Patel; Sarah Y. Kim; Ashwin V. KammulaORCID; Audrey J. MuscatoORCID; Kyle Halliwill; Prasanthi Geda; Kelly L. Klinge; Zhaoming Xiong; Ryan Duggan; Liang Mu; Mitchell D. Yeary; James C. PattiORCID; Tyler M. Balon; Rebecca Mathew; Carey Backus; Domenick E. KennedyORCID; Angeline Chen; Kenton Longenecker; Joseph T. Klahn; Cara L. Hrusch; Navasona Krishnan; Charles W. Hutchins; Jax P. Dunning; Marinka Bulic; Payal Tiwari; Kayla J. Colvin; Cun Lan Chuong; Ian C. Kohnle; Matthew G. ReesORCID; Andrew Boghossian; Melissa RonanORCID; Jennifer A. RothORCID; Meng-Ju WuORCID; Juliette S. M. T. Suermondt; Nelson H. KnudsenORCID; Collins K. Cheruiyot; Debattama R. SenORCID; Gabriel K. Griffin; Todd R. GolubORCID; Nabeel El-BardeesyORCID; Joshua H. Decker; Yi Yang; Magali Guffroy; Stacey Fossey; Patricia Trusk; Im-Meng Sun; Yue Liu; Wei Qiu; Qi Sun; Marcia N. Paddock; Elliot P. FarneyORCID; Mark A. Matulenko; Clay Beauregard; Jennifer M. Frost; Kathleen B. YatesORCID; Philip R. KymORCID; Robert T. MangusoORCID

<jats:title>Abstract</jats:title><jats:p>Immune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance<jats:sup>1,2</jats:sup>. The protein tyrosine phosphatases PTPN2 and PTPN1 are central regulators of inflammation, and their genetic deletion in either tumour cells or immune cells promotes anti-tumour immunity<jats:sup>3–6</jats:sup>. However, phosphatases are challenging drug targets; in particular, the active site has been considered undruggable. Here we present the discovery and characterization of ABBV-CLS-484 (AC484), a first-in-class, orally bioavailable, potent PTPN2 and PTPN1 active-site inhibitor. AC484 treatment in vitro amplifies the response to interferon and promotes the activation and function of several immune cell subsets. In mouse models of cancer resistant to PD-1 blockade, AC484 monotherapy generates potent anti-tumour immunity. We show that AC484 inflames the tumour microenvironment and promotes natural killer cell and CD8<jats:sup>+</jats:sup> T cell function by enhancing JAK–STAT signalling and reducing T cell dysfunction. Inhibitors of PTPN2 and PTPN1 offer a promising new strategy for cancer immunotherapy and are currently being evaluated in patients with advanced solid tumours (ClinicalTrials.gov identifier <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/study/NCT04777994?term=NCT04777994&amp;rank=1">NCT04777994</jats:ext-link>). More broadly, our study shows that small-molecule inhibitors of key intracellular immune regulators can achieve efficacy comparable to or exceeding that of antibody-based immune checkpoint blockade in preclinical models. Finally, to our knowledge, AC484 represents the first active-site phosphatase inhibitor to enter clinical evaluation for cancer immunotherapy and may pave the way for additional therapeutics that target this important class of enzymes.</jats:p>

Palabras clave: Multidisciplinary.

Pp. No disponible

Rock organic carbon oxidation CO2 release offsets silicate weathering sink

Jesse R. ZondervanORCID; Robert G. HiltonORCID; Mathieu DellingerORCID; Fiona J. ClubbORCID; Tobias RoylandsORCID; Mateja OgričORCID

<jats:title>Abstract</jats:title><jats:p>Mountain uplift and erosion have regulated the balance of carbon between Earth’s interior and atmosphere, where prior focus has been placed on the role of silicate mineral weathering in CO<jats:sub>2</jats:sub> drawdown and its contribution to the stability of Earth’s climate in a habitable state<jats:sup>1–5</jats:sup>. However, weathering can also release CO<jats:sub>2</jats:sub> as rock organic carbon (OC<jats:sub>petro</jats:sub>) is oxidized at the near surface<jats:sup>6,7</jats:sup>; this important geological CO<jats:sub>2</jats:sub> flux has remained poorly constrained<jats:sup>3,8</jats:sup>. We use the trace element rhenium in combination with a spatial extrapolation model to quantify this flux across global river catchments<jats:sup>3,9</jats:sup>. We find a CO<jats:sub>2</jats:sub> release of <jats:inline-formula><jats:alternatives><jats:tex-math>$${68}_{-6}^{+18}$$</jats:tex-math><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:msubsup> <mml:mrow> <mml:mn>68</mml:mn> </mml:mrow> <mml:mrow> <mml:mo>−</mml:mo> <mml:mn>6</mml:mn> </mml:mrow> <mml:mrow> <mml:mo>+</mml:mo> <mml:mn>18</mml:mn> </mml:mrow> </mml:msubsup> </mml:math></jats:alternatives></jats:inline-formula> megatons of carbon annually from weathering of OC<jats:sub>petro</jats:sub> in near-surface rocks, rivalling or even exceeding the CO<jats:sub>2</jats:sub> drawdown by silicate weathering at the global scale<jats:sup>10</jats:sup>. Hotspots of CO<jats:sub>2</jats:sub> release are found in mountain ranges with high uplift rates exposing fine-grained sedimentary rock, such as the eastern Himalayas, the Rocky Mountains and the Andes. Our results demonstrate that OC<jats:sub>petro</jats:sub> is far from inert and causes weathering in regions to be net sources or sinks of CO<jats:sub>2</jats:sub>. This raises questions, not yet fully studied, as to how erosion and weathering drive the long-term carbon cycle and contribute to the fine balance of carbon fluxes between the atmosphere, biosphere and lithosphere<jats:sup>2,11</jats:sup>.</jats:p>

Palabras clave: Multidisciplinary.

Pp. No disponible